7CE18C10-61E6-45FA-B9AF-408CD673C0C9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 182.19448094612352
- age_years
- 34
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- NOTCH_SIGNALING+0.577
- ANDROGEN_RESPONSE+0.381
- UNFOLDED_PROTEIN_RESPONSE+0.364
- CHOLESTEROL_HOMEOSTASIS+0.323
- TGF_BETA_SIGNALING+0.317
- MYC_TARGETS_V1+0.307
- PROTEIN_SECRETION+0.305
- MITOTIC_SPINDLE+0.293
- ADIPOGENESIS+0.285
- INTERFERON_ALPHA_RESPONSE+0.282
Top 10 suppressed
- KRAS_SIGNALING_DN-0.312
- SPERMATOGENESIS-0.288
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.243
- COAGULATION-0.199
- ALLOGRAFT_REJECTION-0.158
- MYOGENESIS-0.102
- APICAL_SURFACE-0.090
- TNFA_SIGNALING_VIA_NFKB-0.079
- ANGIOGENESIS-0.067
- INFLAMMATORY_RESPONSE-0.052
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934756 | — | — | 0.916 |
| 2 | 8441B707-EC45-4A38-8B83-99B8D83CCF8B | — | — | 0.916 |
| 3 | EA485E4A-5956-430C-8584-E14D865E3758 | — | — | 0.908 |
| 4 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.907 |
| 5 | 8EFB3C39-094A-4F91-8B8D-EE8A32AC7E1F | — | — | 0.904 |
| 6 | 53426017-24F2-4348-BEE1-05E80B6A0E6B | — | — | 0.899 |
| 7 | SRR934819 | — | — | 0.893 |
| 8 | 194676E1-632C-4B99-A9C8-80E36DD6C85E | — | — | 0.886 |
| 9 | SRR934762 | — | — | 0.886 |
| 10 | 840B7494-6E8E-4518-874A-0C98EF0CBB72 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| NOTCH_SIGNALING | 0.577 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.381 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.364 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.323 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.317 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.307 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.305 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.293 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.285 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.282 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.282 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.279 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.261 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.255 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.244 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.239 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.214 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.196 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.187 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.184 | Inavolisib | — uncovered |